56
Participants
Start Date
October 6, 2020
Primary Completion Date
November 14, 2021
Study Completion Date
December 13, 2021
CVL-865 High dose
High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
Alprazolam 1mg XR
Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
Placebo
Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
CVL-865 low dose
Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
Centre for Human Drug Research, Leiden
Lead Sponsor
Cerevel Therapeutics, LLC
INDUSTRY